



OPEN

A Universal Protein Tag for Delivery of siRNA-Aptamer Chimeras

SUBJECT AREAS:

DRUG DELIVERY

NANOPARTICLES

Hong Yan Liu & Xiaohu Gao

Department of Bioengineering, University of Washington, Seattle, WA 98195, USA.

Received
19 September 2013Accepted
17 October 2013Published
7 November 2013Correspondence and
requests for materials
should be addressed to
X.H.G. (xgao@u.
washington.edu)

siRNA-aptamer chimeras have emerged as one of the most promising approaches for targeted delivery of siRNA due to the modularity of their diblock RNA structure, relatively lower cost over other targeted delivery approaches, and, most importantly, the outstanding potential for clinical translation. However, additional challenges must be addressed for efficient RNA interference (RNAi), in particular, endosomal escape. Currently, vast majority of siRNA delivery vehicles are based on cationic materials, which form complexes with negatively charged siRNA. Unfortunately, these approaches complicate the formulations again by forming large complexes with heterogeneous sizes, unfavorable surface charges, colloidal instability, and poor targeting ligand orientation. Here, we report the development of a small and simple protein tag that complements the therapeutic and targeting functionalities of chimera with two functional domains: a dsRNA binding domain (dsRBD) for siRNA docking and a pH-dependent polyhistidine to disrupt endosomal membrane. The protein selectively tags along the siRNA block of individual chimera, rendering the overall size of the complex small, desirable for deep tissue penetration, and the aptamer block accessible for target recognition. More interestingly, we found that extending the c-terminal polyhistidine segment in the protein tag to 18 amino acids completely abolishes the RNA binding function of dsRBD.

siRNA is of considerable current interest because it can elicit potent, target-specific knockdown of virtually any mRNA, creating new opportunities for personalized medicine and for addressing a broad range of traditionally undruggable disease targets using small molecules^{1–3}. Similar to other antisense approaches, however, cell-specific delivery of siRNA technology *in vivo* still represents a major technical hurdle⁴. To guide siRNA to diseased cells, targeting ligands such as small molecules, lipids, peptides, and proteins have been identified and linked directly to siRNA or on the surface of siRNA nanocarriers^{5–10}. Considering the complex physical and chemical structures of various formulations, the siRNA-targeting ligand-delivery vehicle complexes face difficulty in large-scale production and regulatory approval for clinical uses.

Recently, siRNA-aptamer chimera, employing only RNA molecules, has emerged as a highly promising approach for cell type-specific RNAi, owing to its low immunogenicity, ease of chemical synthesis and modification, small size, and the targeting specificity of aptamers. RNA-based aptamers are identified through *in vitro* enrichment known as SELEX (systematic evolution of ligands by exponential enrichment)^{11–14}. Similar to antibodies, they are capable of binding to various molecular targets including small molecules, proteins, and cells, while offering key advantages as they can be completely identified and produced with desired chemical modifications *in vitro* through automated processes. For aptamer-guided siRNA delivery, exciting works by McNamara, Dassie, and coworkers show that chimeras composed of aptamer targeting prostate specific membrane antigen (PSMA) and siRNA targeting anti-apoptotic genes (Plk1) have been made and optimized^{15,16}. The aptamer block recognizes PSMA on prostate tumor cell surface and leads to chimera cell internalization, whereas the siRNA block enzymatically cleaved from the chimera promotes cell death. Significantly reduced tumor mass was observed in mouse xenograft models of prostate tumor after administration of the chimera, though the exact mechanism of chimera endosomal escape remains unclear¹⁷. This limitation helps explain why high concentrations of chimera were required in these pioneer studies to treat prostate tumors^{15,16}.

An obvious solution to this problem is to combine chimeras with nanocarriers with endosome rupturing capabilities. Common delivery vehicles include lipids, polymers, and inorganic nanoparticles such as gold, silica, magnetic, and semiconductor nanoparticles^{18–22}. For siRNA immobilization, condensation, stabilization against enzymatic degradation, and endosomal escape, virtually all these nanocarriers are positively charged, and so are their siRNA complexes. Unfortunately, the electrostatically induced nanocarrier-chimera condensation almost completely defies the purpose of simple formulation for siRNA clinical translation because the final nanoparticles become complex again, with mixed sizes, surface properties, aptamer conformations and orientations, and batch-to-batch variations. For example, the size difference between the original intact chimeras (nanometers) with the



final large complexes (typically 100 s nanometers) and the chemical composition of the nanocarriers can drastically change chimera's targeting profile, *in vivo* biodistribution, and clearance²³. Furthermore, it is ideal to make the aptamer loop structure exposed and the siRNA block hidden for specific binding, but electrostatic condensation with cationic nanocarriers does not warrant that selectivity. As demonstrated previously, immobilizing siRNA-aptamer chimeras onto cationic nanoparticles *via* the siRNA end offers significantly improved silencing effect compared to condensing chimeras onto cationic nanoparticles through random sites²⁴. This is understandable since (1) exposure of the siRNA end would only increase the chances of non-specific binding and reduce the stability siRNA against enzymatic degradation; and (2) interaction between cationic nanocarriers with anionic aptamers could alter aptamers' conformation and targeting capability²⁵. Therefore, it is of critical importance to design a delivery system that is simple for potential regulatory approval and mass production, universal for all siRNA-aptamer chimera, neutral and siRNA-binding specific to ensure aptamer targeting, and small to avoid major alteration of chimera's biodistribution profile. A system simultaneously achieving these features could expedite clinically translation of the highly promising siRNA-aptamer chimera technology.

Here, we report the development of a small protein tag for efficient delivery of siRNA-aptamer chimeras. As shown in **Figure 1**, the protein tag is composed of two functional domains: a dsRBD used as a siRNA docking module and a pH-dependent polyhistidine to help disrupt the endosomal membrane. The dsRBD is the N-terminal region (20 Kda) of human protein kinase that binds dsRNA in a sequence-independent fashion^{26,27}. Because aptamers are typically ssRNA with complex secondary structures, dsRBD does not bind with them (dsRBD only tolerates small bulges) and thus will selectively bind chimera through the siRNA end, leaving the aptamer end accessible.

To add endosomal escape functionality, a short histidine (His) oligomer is added to the C-terminus of the dsRBD. His has been incorporated into a number gene carriers because its endosomal buffering capacity promoting drug cytoplasmic release^{28,29}. His molecules have a pKa value of approximately 6. At neutral pH (such as in circulation), they are mainly deprotonated (uncharged), which is desirable over positively charged counterparts due to reduced accumulation within the RES (reticuloendothelial system). In acidic compartments such as endosome, His becomes protonated and facilitates osmotic swelling that leads to cargo release, a mechanism proposed as the proton sponge effect³⁰. Overall, this protein tag is equally small, simple, and biodegradable as siRNA-aptamer chimera, while perfectly complementing chimera's functionalities. When complexed together, they remain small in size, discrete and stable in

solution, low positive charge for circulation, and simultaneously achieve therapeutic, targeting, and endosomal escaping capabilities.

Results

Expression and characterization of dsRBD-His₁₈ protein tag. To add endosomal escape capability, a short polyhistidine peptide was added to dsRBD. The dsRBD domain comes from the first 172 amino acids of human protein kinase R (*hPKR*), and has two double-strand RNA binding motifs (dsRBM1 and dsRBM2) for cooperative and dsRNA-specific binding³¹. Because dsRBM1 towards the N terminal dominates the binding with dsRNA³², we introduced the histidine peptide towards the C terminal (**Figure 1**) to minimize impact on dsRBD's biological activity. In theory, the endosomal escape capability should increase with longer His chain; on the other hand, long His chain could potentially interfere with dsRBD protein folding and binding. To achieve a balance, dsRBD with C-terminal Histidines of various lengths (His_n, n = 0, 12, 18, and 24) were cloned into the PET28a (+) vector. BamH1 and Xho1 restriction enzyme sites were introduced to the 5'- and 3'-flanking region by PCR, respectively. Because all the genetic constructs contain His₆ at the N-terminal from the cloning vector (this N-terminal His₆ has been previously proved to have no impact on dsRBD binding)²⁶, the total numbers of His encoded by the final constructs are 6, 18, 24, and 30, respectively (sequences see **Methods**).

Post expression and purification, the resulted protein tags were analyzed with sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE, **Figure 2a**). The sizes of four protein tags show in excellent agreement with theoretical values (**Figure 1**). To assess their dsRNA binding activity, siRNA-aptamer chimera labeled with fluorophore FAM were incubated with the protein tags and probed with gel electrophoresis (1% agarose). As shown in **Figure 2b**, the dsRNA binding capability of dsRBD with His₁₂ at the C terminus (total His₁₈) is well preserved compared with dsRBD without a C-terminal histag insertion. The minimum RNA length for high affinity binding with dsRBD has been determined to be 16 base-pairs²⁶. At the current RNA length, the siRNA segment and the adjacent short stem in the aptamer structure can bind with 1–2 copies of dsRBD. However, it has been well documented that only the first dsRBD binds to RNA stably, while, at high dsRBD/RNA ratio, a second copy of dsRBD can bind, but at significantly lower affinity^{26,33}. Using unmodified dsRBD and siRNA alone, similar dsRBD-siRNA binding profiles have been observed previously by Kim and coworkers, who also show that the enzymatic stability of siRNA is significantly enhanced upon binding with dsRBD³⁴.

It is important to mention that a key difference of our technology compared to these prior works utilizing dsRBD for siRNA




Figure 1 | Schematics of protein tags for siRNA-aptamer chimera delivery. Chimera composed of an aptamer block targeting PSMA and a siRNA block targeting GFP forms a hair-pin like structure. Protein tags specifically bound to the stem region (dsRNA) of the chimera complements it with endosomal escape capability. Protein tags with varying lengths of polyhistidines, as shown in the domain architectures, are engineered to achieve balanced endosomal escape and RNA binding functionalities.




Figure 2 | Characterization of protein tags with varying lengths of polyhistidine and the siRNA-aptamer chimera. (a) SDS-PAGE analysis of protein tags composed of a dsRBD binding domain and polyhistidines at the two termini (total number of His: 6, 18, 24, and 30), in reference to protein ladder shown to the left. Motility patterns of the four protein tags are in agreement with their calculated molecular weights of 22.6 kDa (His_6), 24.8 kDa (His_{18}), 25.8 kDa (His_{24}), and 26.8 kDa (His_{30}). (b) Characterization of dsRNA binding capability of the four protein tags with agarose gel electrophoresis. Chimera labeled with fluorophore (FAM) was incubated with the protein tags at protein/chimera molar ratios of 1, 2, or 4 for 1 h at 4 °C. The dsRNA binding capability of dsRBD- His_{18} is well preserved compared to the original dsRBD- His_6 , whereas dsRBD- His_{24} and dsRBD- His_{30} completely lose dsRNA binding activity. (c) Evaluation of targeting specificity of the aptamer block in chimera. PSMA-positive LNCaP cells and PSMA-negative PC3 cells are treated with complex of Cy3-labeled chimera and dsRBD- His_{18} for 12 h. Fluorescence microscopy reveals selective binding of the complex to LNCaP cells, but not PC3 cells. Scale bar: 50 μm . (d) Evaluation of silencing functionality of the siRNA block. The chimera and conventional siRNA targeting GFP (positive control) are transfected into GFP-expressing C4-2 prostate cancer cells using Lipofectamine. The silencing effect of the chimera is indistinguishable with the positive control. Scale bar: 250 μm .

delivery^{27,34} is that we do not introduce highly positively charged peptides. Although positively charged nanocarriers promote siRNA cell entry, it is well known that they are also quickly cleared by the RES, increase non-specific binding with cells and cytotoxicity³⁵. Furthermore, as aforementioned, avoiding positive charges in carrier design is particularly important for siRNA-aptamer chimera because excessive positive charges could non-specifically interact with aptamer and affect its targeting capability.

More interestingly, the gel electrophoresis experiments also reveal that extending the C-terminal His by another 6 or 12 amino acids completely abolish dsRBD's binding activity. Therefore, for the following gene expression regulation studies we chose the dsRBD with a total of 18 His due to its balanced dsRNA binding and endosomal escape functionalities, in comparison with the original dsRBD with no C-terminus His as a control.

Design, synthesis, and characterization of siRNA-aptamer chimera. To evaluate the universal protein tag for siRNA-aptamer chimera, we first designed and made a chimera based on the protocols described by Dassie and coworkers, taking advantage of the shortened aptamer sequence for specific targeting of PSMA as well as the optimized siRNA strands with enhanced therapeutic potency¹⁵. The PSMA targeting aptamer was kept in our chimera, because PSMA has been identified as one of the most attractive cell surface markers for both prostate epithelial cells and neovascular endothelial cells³⁶. Accumulation and retention of PSMA targeting probes at the site of tumor growth is the basis of radioimmuno-scintigraphic scanning (e.g., ProstaScint scan) and targeted therapy for human prostate cancer metastasis. We replaced their siRNA sequence with a siRNA silencing GFP expression, because GFP is

the best model for quantitative assessment of the silencing effect using optical imaging and flow cytometry.

The long ssRNA composed of PSMA aptamer and siRNA anti-sense strand (Figure 1) was prepared by *in vitro* transcription with the presence of 2' fluoro-modified pyrimidies for improved resistance to ribonucleases. It has been shown previously that 2'-F modification is compatible with dsRBD binding unlike 2'-H or 2'-OCH₃ substitutes^{26,37}. The transcript was annealed to chemically synthesized siRNA sense strand. Before combining the chimera with our small protein tag, we first tested the activities of the chimera. To test the targeting function of the aptamer block, PSMA-positive LNCaP and PSMA-negative PC3 prostate tumor cells were incubated with dye-labeled chimera. As shown in Figure 2c, the chimera selectively binds and enters LNCaP cells indicating targeting specificity. To test the silencing effect separately, the chimera was transfected into GFP-expressing C4-2 prostate tumor cells (a derivative of LNCaP) using conventional transfection agents, Lipofectamine. As shown in Figure 2d, the silencing effect is indistinguishable with the positive control using siRNA only, proving that chimera can be enzymatically processed intracellularly to generate functional siRNA.

Targeting delivery and silencing in cells. With the biological activities of our protein tag and siRNA-aptamer chimera separately characterized, we proceeded to evaluate the gene silencing effect of this simple yet functionally highly complementary protein tag in siRNA-aptamer chimera delivery. GFP-expressing C4-2 cell line was used as a model because of the advantages of fluorescence imaging techniques such as microscopy and quantitative flow cytometry. Figure 3a–f shows confocal images of the C4-2 cells without treatment, treated with GFP-siRNA alone, chimera alone, a



random sequenced siRNA with the protein tag (His₁₈), chimera with protein tag (His₆), and chimera with protein tag (His₁₈). Qualitatively, only the experimental treatment, chimera with protein tag (His₁₈), clearly shows GFP silencing, whereas none of the five control treatments leads to significant suppression of GFP expression.

Quantitative flow cytometry studies further confirm this result (Figure 3g–l). At the current gate value set for GFP fluorescence intensity, the original untreated cells showed a GFP-negative population of 17.4%. Treating the cells with a random sequenced siRNA with protein tag (His₁₈) shows virtually no change in this population (difference: 5.4% of total cell population, within error range) proving sequence-specific silencing of RNAi. For cells treated with GFP

siRNA and chimera, the GFP negative cells only increase by 7.6% and 12.2% of the total cell population respectively. Even by increasing the chimera concentration by ten times (1 μ M), the total GFP-negative cell population only increase by <20% (Supplementary Figure S1), strongly suggesting the need of carrier materials. Direct comparison of the chimera tagged by dsRBD-His₆ and dsRBD-His₁₈ shows major difference in silencing efficiency, too (14.6% and 59.6% change). Taken together, these results clearly indicate that (1) chimera alone at concentration commonly used in RNAi experiments does not lead to effective silencing, and (2) His₁₈ is remarkably more effective than His₆ in endosomal destabilization since the dsRBD block is identical in structure and function. To put the silencing




Figure 3 | Assessment of gene knockdown with confocal microscopy and flow cytometry. GFP expressing C4-2 cells are treated with chimera-dsRBD-His₁₈ complex and five controls, and the silencing effect is assessed with confocal microscopy (a–f) and quantified with flow cytometry (g–l). For confocal imaging, the panels from left to right are DIC, fluorescence, and merged images. In contrast to the control conditions (a, g) no treatment, (b, h) scrambled siRNA with dsRBD-His₁₈, (c, i) siRNA against GFP only, (d, j) chimera complexed with dsRBD-His₆, (e, k) chimera only (absence of transfection agents), the experimental group of chimera complexed with dsRBD-His₁₈ (f, l) shows significantly higher GFP knockdown. Scale bar as shown in (a) is consistent in the microscopy images, 20 μ m.



efficiency of dsRBD-His₁₈ in the context of those of conventional RNA delivery vehicles such as Lipofectamine, quantitative flow cytometry was also conducted. In agreement with the microscopy results shown in **Figure 2d**, Lipofectamine reduces GFP-negative cells from the original 17.4% to 91.6% (74.2% change, **Supplementary Figure S2**), which is slightly more efficient than the protein tag. However, it is important to note that Lipofectamine delivers chimera into cells mainly *via* electrostatic interactions (positively charged Lipofectamine and negatively charged cell surface, non-targeted delivery), whereas our protein tag delivers chimera by cell type-specific molecular recognition (targeted delivery). It is also worth mentioning that the molar ratio of mixing chimera with protein tag is 1 : 2 because the siRNA block can bind up to 2 copies of dsRBD, although the second copy has very weak binding affinity. Indeed, changing the binding ratio to 1 or 4 does not affect the RNAi efficiency (**Supplementary Figure S3**).

To further confirm the difference in endosomal escape capability between the two protein tags (dsRBD-His₆ and dsRBD-His₁₈), we performed a dual color imaging assay using non-fluorescence LNCaP cells. In this experiment, chimera was labeled with Cy3 and endosome/lysosome was marked with a LysoTracker (spectrally distinguishable green fluorescence). Direct contrast in chimera distribution and intracellular density of endosome/lysosome was observed between the two protein tags. As shown in **Figure 4**, Cy3-labeled chimera evenly distributes inside cells when tagged by dsRBD-His₁₈, whereas dsRBD-His₆ treated cells show much higher density of endosomes and lysosomes and lower level of Cy3 fluorescence. This confocal imaging comparison directly explains the difference between the two protein tags in RNAi efficiency, and unambiguously demonstrates the superior endosome escape capability of dsRBD-His₁₈ over dsRBD-His₆.

Cytotoxicity. Lastly, we probed the cytotoxicity of the best performing protein tag dsRBD-His₁₈ using a standard cell viability assay (CellTiter-Blue®). The assay is based on the ability of living cells to convert a redox dye (resazurin) into a fluorescent end product (resorufin). Nonviable cells lose metabolic capacity and thus do not generate fluorescent signals. As illustrated in **Figure 5**, virtually no toxicity was detected up to a concentration four times as high as the one used in the delivery work in reference to the untreated control. This is perhaps not too surprising due to the biocompatibility of dsRBD, a small protein of human origin. More importantly, for future *in vivo* applications, we envision that the small protein tag would have improved clearance capability compared with synthetic polymers and inorganic nanoparticles used for siRNA delivery.

Discussion

siRNA-aptamer chimera is one of the most promising approaches for cell type-specific RNAi, owing to its low immunogenicity, ease of chemical synthesis and modification, small size, and the modularity of both the targeting aptamer block and the therapeutic siRNA segment. More importantly, employing only RNA molecules, the simple formulation of chimera-based targeted siRNA therapy leads to outstanding clinical translation^{15,16}. Due to the incapability of chimera to efficiently escape endosome, delivery nanocarriers are needed. However, almost all current targeted siRNA delivery formulations involve cationic nanocarriers such as polymers, inorganic nanoparticles, peptides, and proteins^{7,19,20,27,28,38–44}. Unfortunately, these conventional siRNA nanocarriers are unsuitable for chimera delivery, and, in fact, reverse the signature property of chimera, simple formulation for regulatory approval and clinical translation^{15,16}. This is because the charge induced complex formation is basically an aggregation process, which lacks control over aggregate size, shape, stoichiometry, chimera orientation, aptamer functionality, and reproducibility during scale-up production. In addition, the final complexes often carriers positive charges as well, which is unfavorable for systemic uses²³. As a result, first clinical trials of siRNA duplexes are mainly limited to local administrations^{45–48}.

Our protein tag does not rely on high positive charge to interact with RNA molecules. In fact, it only recognizes relatively long dsRNAs (>16 bp) such as the siRNA segment and the short stem region of the aptamer in our chimera molecule. Extensive biochemistry investigations have shown that for the current length of the chimera, maximum two copies of dsRBD can bind to it with differential affinity (the first copy binds much stronger than the second copy). The gene silencing experiments conducted here reflect this effect since mixing chimera with 1× or 2× protein tags does not affect the silencing efficiency. Considering the molecular weights of the chimera (28.8 kDa) and the protein tag (24.8 kDa), molecular weight of the final complex at 1 : 1 binding will become 53.6 kDa. Based on well-documented size effect for *in vivo* drug delivery⁴⁹, this size is sufficiently large to reduce premature renal clearance while still small enough for deep tissue penetration. For example, by tagging siRNA-aptamer chimera with a 20 kDa PEG, its *in vivo* circulating half-life has been shown to increase from approximately 30 min to 30 hours¹⁵; whereas large nanoparticles (>30 nm) have been shown to be ineffective in tumor treatment except for some hyperpermeable tumors⁵⁰.

In conclusion, to solve the endosome escape problem of the highly promising siRNA-aptamer chimera based therapy, we have designed a dual-block small protein by combining dsRBD and polyhistidine




Figure 4 | Comparison of endosomal escape of protein tags, dsRBD-His₆ and dsRBD-His₁₈. Cy3-labeled chimera complexed with the two protein tags are added to LNCaP cells for 12 h, followed by LysoTracker Green staining for 4 h. Confocal laser scanning microscopy reveals homogeneous distribution of fluorescence of chimera tagged with dsRBD-His₁₈ and reduced endosome density compared to chimera complexed with dsRBD-His₆.



TYRQKQGVVLKYQELPNSGPPHRRFTFQVIIDGREGPEGEGRSKKEAKNAA-
AKLAVEILNKEKKA VSP LLLTTNSSEGLSMGN YIGLINRIA QKRLTVNYEQC-
ASGVHGPEGFHYKCKMGQKEYSIGTGSTKQEA KQLA AAKLAYLQLSEETS VVH-
HH

Single colonies were selected and grown at 37°C for 12 h in Circlegrow medium containing 30 µg/ml kanamycin. Overnight cultures were diluted at 1 : 100 (v/v) into fresh medium and incubated at 37°C until the OD₆₀₀ values reach 0.5–1.0. Expression was induced by addition of isopropyl-β-D-thiogalactopyranoside (IPTG, 1 mM), and cell growth was continued for another 4–5 hour at 30°C. Cells were harvested by centrifugation (Beckman JA-10 rotor) at 10,000 g for 10 min and stored at –20°C.

Cells were suspended in Bug-Buster Mix (Novagen) with 5 ml reagent per gram of wet cell paste. Bug Buster Mix was added with protease inhibitor EDTA-free cocktail (Pierce), 10% glycerol, and 1.0 mM THP (Novagen). The cell suspensions were incubated on a shaker platform for 30 min at room temperature. Insoluble cell debris was removed by centrifugation (Beckman TL120) at 20,000× g for 20 min at 4°C. The soluble extracts were loaded onto affinity columns with Ni-charged His Bind Resin (Novagen). Following washing with binding buffer and washing buffer, the desired proteins were eluted with 6 volume elution buffer (Novagen). The eluted proteins were dialyzed with PBS containing 10% glycerol and 0.1% (v/v) β-mercaptoethanol for 24 hours.

Purified proteins were probed using 12% SDS-PAGE and stained with Coomassie Brilliant Blue G-250 (Bio-Rad). Protein concentrations were determined with the Bio-Rad Protein Assay with bovine serum albumin as the standard.

Functional characterization of siRNA-aptamer chimera. To test the functionality of the siRNA block, the chimera described above and GFP siRNA control (Qiagen) at a final concentration of 50 nM were transfected into C4-2 prostate cancer cells stably expressing GFP using Lipofectamine RNAi MAX (Invitrogen) following the instructions provided by the manufacturer. To evaluate the targeting specificity of the aptamer block, PSMA-positive LNCaP cells and PSMA-negative PC3 cells were treated with complex of chimera and dsRBD-His₁₈ (chimera/protein tag molar ratio at 1 : 2, 100 nM chimera) in serum free medium for 2 hours, followed by incubation in complete medium for another 12 h. DAPI (30 nM) was added to stain cell nuclei. Fluorescent images were captured on an Olympus IX-71 inverted microscope equipped with 5 long-pass filters and a colored CCD camera.

Characterization of RNA binding capability of the four protein tags. The binding capabilities of the four polyhistidine modified dsRBD proteins were evaluated by native agarose gel. The chimera was labeled with FAM at the 5' end of siRNA's sense strand (IDT). To prepare chimera/dsRBD complex, chimera (5 µM, 10 µM) was incubated with the protein tags at protein/chimera molar ratios of 1, 2, or 4 for 1 h at 4°C. Bound chimera and unbound chimera were quantified on 1% agarose gel using a Macro imaging system (Lighttools Research, CA).

Evaluation of endosomal escape. PSMA-expressing LNCaP cells were seeded on 35 mm glass-bottom petri dishes (MatTek Corp) at a density of 5 × 10⁴ cells/well for 24 hours in RPMI 1640 supplemented with 10% FCS. Complexes of chimera labeled with Cy3 (IDT) and protein tags (His₆ and His₁₈) were added to LNCaP cells in serum-free medium for 2 hours, followed by incubation in complete medium for 12 hours. LysoTracker® Green DND-26 (80 nM, Invitrogen) was then added for 4 hours at 37°C. Images were captured on a confocal laser scanning microscope (LSM 510, Carl Zeiss, Germany).

Microscopy and flow cytometry studies of gene knockdown efficacy. C4-2 prostate cancer cells expressing GFP were seeded into 35 mM glass-bottom petri dishes for confocal imaging or 6-well plates for flow cytometry. Cells were treated with chimera & dsRBD-His₁₈ and compared with five control groups including no treatment, treated with GFP-siRNA alone, chimera alone, a random sequenced siRNA with the protein tag (His₁₈), and chimera with protein tag (His₆) for 2 h in serum free media and then incubated in complete media for 60 h. Confocal images were again obtained with LSM 510 confocal microscope equipped with argon (488 nm) and HeNe (543 nm) lasers; and quantitative flow cytometry investigation was done on a BD FACSCantoII flow cytometer.

Cytotoxicity assay. LNCaP cells were seeded in 96-well plate at 4 × 10³/well for 24 hours, and then treated with different concentrations of dsRBD-His₁₈ protein tag for 72 hours. CellTiter-Blue reagent (20 µl) was added into each well. After 4 h incubation at 37°C, cell viability was assessed by fluorescence intensity at 590 nm (excitation 570 nm) on a TECAN infinite M200 microplate reader.

- Dykxhoorn, D. M., Novina, C. D. & Sharp, P. A. Killing the messenger: short RNAs that silence gene expression. *Nat. Rev. Mol. Cell Biol.* **4**, 457–467 (2003).
- Hannon, G. J. RNA interference. *Nature* **418**, 244–251 (2002).
- Scherer, L. J. & Rossi, J. J. Approaches for the sequence-specific knockdown of mRNA. *Nat. Biotechnol.* **21**, 1457–1465 (2003).
- Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. *Nat. Rev. Drug Discov.* **8**, 129–138 (2009).
- Chiu, Y. L., Ali, A., Chu, C. Y., Cao, H. & Rana, T. M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. *Chem. Biol.* **11**, 1165–1175 (2004).

- Jeong, J. H., Mok, H., Oh, Y. K. & Park, T. G. siRNA conjugate delivery systems. *Bioconjug. Chem.* **20**, 5–14 (2009).
- Moschos, S. A. *et al.* Lung delivery studies using siRNA conjugated to TAT(48–60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. *Bioconjug. Chem.* **18**, 1450–1459 (2007).
- Nishina, K. *et al.* Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. *Mol. Ther.* **16**, 734–740 (2008).
- Soutschek, J. *et al.* Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature* **432**, 173–178 (2004).
- Wolfrum, C. *et al.* Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. *Nat. Biotechnol.* **25**, 1149–1157 (2007).
- Bock, L. C., Griffin, L. C., Latham, J. A., Vermaas, E. H. & Toole, J. J. Selection of single-stranded-DNA molecules that bind and inhibit human thrombin. *Nature* **355**, 564–566 (1992).
- Ellington, A. D. & Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands. *Nature* **346**, 818–822 (1990).
- Hermann, T. & Patel, D. J. Biochemistry - Adaptive recognition by nucleic acid aptamers. *Science* **287**, 820–825 (2000).
- Nimjee, S. M., Rusconi, C. P. & Sullenger, B. A. in *Annual Rev. Med.* **56**, 555–583 (2005).
- Dassie, J. P. *et al.* Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. *Nat. Biotechnol.* **27**, 839–849 (2009).
- McNamara, J. O. 2nd *et al.* Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. *Nat. Biotechnol.* **24**, 1005–1015 (2006).
- Levy-Nissenbaum, E., Radovic-Moreno, A. F., Wang, A. Z., Langer, R. & Farokhzad, O. C. Nanotechnology and aptamers: applications in drug delivery. *Trends Biotechnol.* **26**, 442–449 (2008).
- Derfus, A. M., Chen, A. A., Min, D. H., Ruoslahti, E. & Bhatia, S. N. Targeted quantum dot conjugates for siRNA delivery. *Bioconjug. Chem.* **18**, 1391–1396 (2007).
- Elbakry, A. *et al.* Layer-by-layer assembled gold nanoparticles for siRNA delivery. *Nano Lett.* **9**, 2059–2064 (2009).
- Medarova, Z., Pham, W., Farrar, C., Petkova, V. & Moore, A. In vivo imaging of siRNA delivery and silencing in tumors. *Nat. Med.* **13**, 372–377 (2007).
- Meng, H. *et al.* Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. *ACS Nano* **4**, 4539–4550.
- Xia, T. *et al.* Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. *ACS Nano* **3**, 3273–3286 (2009).
- Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. *Mol. Pharm.* **5**, 505–515 (2008).
- Bagalkot, V. & Gao, X. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. *ACS Nano* **5**, 8131–8139 (2011).
- Walter, J.-G., Kolkpınar, O. Z., Friehs, K., Stahl, F. & Scheper, T. Systematic Investigation of Optimal Aptamer Immobilization for Protein² Microarray Applications. *Anal. Chem.* **80**, 7372–7378 (2008).
- Bevilacqua, P. C. & Cech, T. R. Minor-groove recognition of double-stranded RNA by the double-stranded RNA-binding domain from the RNA-activated protein kinase PKR. *Biochemistry* **35**, 9983–9994 (1996).
- Eguchi, A. *et al.* Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. *Nat. Biotechnol.* **27**, 567–U110 (2009).
- Pichon, C., Goncalves, C. & Midoux, P. Histidine-rich peptides and polymers for nucleic acids delivery. *Adv. Drug Del. Rev.* **53**, 75–94 (2001).
- Midoux, P., Pichon, C., Yaouanc, J. J. & Jaffres, P. A. Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. *Br. J. Pharmacol.* **157**, 166–178 (2009).
- Behr, J. P. The proton sponge: A trick to enter cells the viruses did not exploit. *Chimia* **51**, 34–36 (1997).
- Nanduri, S., Carpick, B. W., Yang, Y. W., Williams, B. R. G. & Qin, J. Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. *Embo J.* **17**, 5458–5465 (1998).
- Green, S. R. & Mathews, M. B. 2 Rna-Binding Motifs in the Double-Stranded Rna-Activated Protein-Kinase, Dai. *Genes Dev.* **6**, 2478–2490 (1992).
- Kim, I., Liu, C. W. & Puglisi, J. D. Specific recognition of HIV TAR RNA by the dsRNA binding domains (dsRBD1-dsRBD2) of PKR. *J. Mol. Biol.* **358**, 430–442 (2006).
- Kim, J., Lee, S. H., Choe, J. & Park, T. G. Intracellular small interfering RNA delivery using genetically engineered double-stranded RNA binding protein domain. *J. Gene Med.* **11**, 804–812 (2009).
- Ko, Y. T., Kale, A., Hartner, W. C., Papahadjopoulos-Sternberg, B. & Torchilin, V. P. Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery. *J. Controlled Release* **133**, 132–138 (2009).
- Chang, S. S., Reuter, V. E., Heston, W. D. W. & Gaudin, P. B. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. *Urology* **57**, 801–805 (2001).



37. Nallagatla, S. R. & Bevilacqua, P. C. Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. *RNA* **14**, 1201–1213 (2008).
38. Davis, M. E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. *Mol. Pharm.* **6**, 659–668 (2009).
39. Green, J. J. *et al.* Electrostatic Ligand Coatings of Nanoparticles Enable Ligand-Specific Gene Delivery to Human Primary Cells. *Nano Lett.* **7**, 874–879 (2007).
40. Howard, K. A. *et al.* RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. *Mol. Ther.* **14**, 476–484 (2006).
41. Liu, X. *et al.* The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. *Biomaterials* **28**, 1280–1288 (2007).
42. Qi, L. & Gao, X. Quantum dot-amphiphilic nanocomplex for intracellular delivery and real-time imaging of siRNA. *ACS Nano* **2**, 1403–1410 (2008).
43. Qi, L. & Gao, X. Emerging application of quantum dots for drug delivery and therapy. *Exp. Opin. Drug Del.* **5**, 263–267 (2008).
44. Probst, C. E., Zrazhevskiy, P., Bagalkot, V. & Gao, X. H. Quantum dots as a platform for nanoparticle drug delivery vehicle design. *Adv. Drug Del. Rev.* **65**, 703–718 (2013).
45. Bitko, V., Musiyenko, A., Shulyayeva, O. & Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. *Nat. Med.* **11**, 50–55 (2005).
46. DeVincenzo, J. *et al.* Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). *Antiviral Res.* **77**, 225–231 (2008).
47. Li, B. J. *et al.* Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque. *Nat. Med.* **11**, 944–951 (2005).
48. Reich, S. *et al.* Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. *Mol. Vision* **9**, 210–216 (2003).
49. Longmire, M., Choyke, P. L. & Kobayashi, H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. *Nanomedicine* **3**, 703–717 (2008).
50. Cabral, H. *et al.* Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. *Nat. Nanotechnol.* **6**, 815–823 (2011).

Acknowledgements

This work was supported in part by NIH (R01CA140295, CA150301), the Department of Bioengineering, and the Office of Research at University of Washington. We are also grateful to Drs. Eva Corey and Bob Vessella for their prostate tumor cell lines and fruitful discussions.

Author contributions

X.H.G. conceived the idea. H.Y.L. and X.H.G. designed the experiments. H.Y.L. performed the experiments. H.Y.L. and X.H.G. analyzed the data and wrote the paper.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Liu, H.Y. & Gao, X. A Universal Protein Tag for Delivery of SiRNA-Aptamer Chimeras. *Sci. Rep.* **3**, 3129; DOI:10.1038/srep03129 (2013).



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported license. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0>